Risankizumab (Skyrizi)

Indications

Moderate-to-severe CD in patients ≥16 years old; moderate-to-severe UC in adults

Contraindications

Hypersensitivity to the active substance or excipients; clinically important active infections (e.g. tuberculosis)

Preparations Available

Intravenous infusion

Quantity

Dose: Induction (CD), 600mg IV every 4 weeks (3 doses on weeks 0, 4 and 8); maintenance: 360mg (SC) every 8 weeks, starting week 12; induction (UC), 1.2g IV every 4 weeks (3 doses on weeks 0, 4 and 8); Maintenance: 180mg (SC) every 8 weeks, starting week 12 or or 360mg (SC) every 8 weeks, starting week 12 if inadequate improvement after induction

Sizes Available

150mg pre-filled disposable injection, £3,326.09

Price

600mg/10ml concentrate for infusion vial (1), £3326.09

More on: Biologics